The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) recently recommended granting market authorization for Abiraterone Accord for the treatment of metastatic prostate cancer. Abiraterone is "a hormone antagonist that inhibits the production of androgens in the testes, adrenal glands and prostatic tumour tissues."
To read more about this recommendation, click here.
No comments:
Post a Comment